Side-effects of roflumilast

The Lancet

Volumn 379, Issue 9817, 2012, Pages 710-711

  Gupta, Steve ^a  

^a Verdugo Hills Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFLUMILAST;

ANXIETY DISORDER; CANCER INCIDENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; HOSPITAL ADMISSION; HUMAN; INSOMNIA; INTRACTABLE DIARRHEA; LETTER; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT REDUCTION;

EID: 84863282303     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60304-3     Document Type: Letter

References (4)

1. PM Calverley, KF Rabe, UM Goehring, S Kristiansen, LM Fabbri, FJ Martinez for the M2-124 and M2-125 study groups Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694
2. LM Fabbri, PM Calverley, JL Izquierdo-Alonso for the M2-127 and M2-128 study groups Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
3. Center for Drug Evaluation and Research Application number 022522Orig1s000: medical review(s) http://www.accessdata.fda.gov/drugsatfda- docs/nda/2011/022522Orig1s000MedR.pdf (accessed Nov 21, 2011).
4. US Food and Drug Administration Analysis of malignancy for roflumilast 500 mcg group vs placebo http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/20Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM208710.pdf (accessed Oct 21, 2011).